TY - JOUR
T1 - Race-free estimated glomerular filtration rate equation in kidney transplant recipients
T2 - development and validation study
AU - Raynaud, Marc
AU - Al-Awadhi, Solaf
AU - Juric, Ivana
AU - Divard, Gillian
AU - Lombardi, Yannis
AU - Basic-Jukic, Nikolina
AU - Aubert, Olivier
AU - Dubourg, Laurence
AU - Masson, Ingrid
AU - Mariat, Christophe
AU - Prié, Dominique
AU - Pernin, Vincent
AU - Le Quintrec, Moglie
AU - Larson, Timothy S.
AU - Stegall, Mark D.
AU - Bikbov, Boris
AU - Ruggenenti, Piero
AU - Mesnard, Laurent
AU - Ibrahim, Hassan N.
AU - Nielsen, Marie Bodilsen
AU - Matas, Arthur J.
AU - Nankivell, Brian J.
AU - Benjamens, Stan
AU - Pol, Robert A.
AU - Bakker, Stephan J.L.
AU - Jouven, Xavier
AU - Legendre, Christophe
AU - Kamar, Nassim
AU - Smith, Byron H.
AU - Wadei, Hani M.
AU - Durrbach, Antoine
AU - Vincenti, Flavio
AU - Remuzzi, Giuseppe
AU - Lefaucheur, Carmen
AU - Bentall, Andrew J.
AU - Loupy, Alexandre
N1 - Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Objective To compare the performance of a newly developed race-free kidney recipient specific glomerular filtration rate (GFR) equation with the three current main equations for measuring GFR in kidney transplant recipients. Design Development and validation study setting 17 cohorts in Europe, the United States, and Australia (14 transplant centres, three clinical trials). ParticiPants 15 489 adults (3622 in development cohort (Necker, Saint Louis, and Toulouse hospitals, France), 11 867 in multiple external validation cohorts) who received kidney transplants between 1 January 2000 and 1 January 2021. Main OutcOMe Measure The main outcome measure was GFR, measured according to local practice. Performance of the GFR equations was assessed using P30 (proportion of estimated GFR (eGFR) within 30% of measured GFR (mGFR)) and correct classification (agreement between eGFR and mGFR according to GFR stages). The race-free equation, based on creatinine level, age, and sex, was developed using additive and multiplicative linear regressions, and its performance was compared with the three current main GFR equations: Modification of Diet in Renal Disease (MDRD) equation, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation, and race-free CKD-EPI 2021 equation. results The study included 15 489 participants, with 50 464 mGFR and eGFR values. The mean GFR was 53.18 mL/min/1.73m2 (SD 17.23) in the development cohort and 55.90 mL/min/1.73m2 (19.69) in the external validation cohorts. Among the current GFR equations, the race-free CKD-EPI 2021 equation showed the lowest performance compared with the MDRD and CKD-EPI 2009 equations. When race was included in the kidney recipient specific GFR equation, performance did not increase. The race-free kidney recipient specific GFR equation showed significantly improved performance compared with the race-free CKD-EPI 2021 equation and performed well in the external validation cohorts (P30 ranging from 73.0% to 91.3%). The race-free kidney recipient specific GFR equation performed well in several subpopulations of kidney transplant recipients stratified by race (P30 73.0-91.3%), sex (72.7-91.4%), age (70.3-92.0%), body mass index (64.5-100%), donor type (58.5-92.9%), donor age (68.3-94.3%), treatment (78.5-85.2%), creatinine level (72.8-91.3%), GFR measurement method (73.0-91.3%), and timing of GFR measurement post-transplant (72.9-95.5%). An online application was developed that estimates GFR based on recipient’s creatinine level, age, and sex (https://transplant-prediction-system.shinyapps.io/eGFR_equation_KTX/). cOnclusiOn A new race-free kidney recipient specific GFR equation was developed and validated using multiple, large, international cohorts of kidney transplant recipients. The equation showed high accuracy and outperformed the race-free CKD-EPI 2021 equation that was developed in individuals with native kidneys. trial registratiOn ClinicalTrials.gov NCT05229939.
AB - Objective To compare the performance of a newly developed race-free kidney recipient specific glomerular filtration rate (GFR) equation with the three current main equations for measuring GFR in kidney transplant recipients. Design Development and validation study setting 17 cohorts in Europe, the United States, and Australia (14 transplant centres, three clinical trials). ParticiPants 15 489 adults (3622 in development cohort (Necker, Saint Louis, and Toulouse hospitals, France), 11 867 in multiple external validation cohorts) who received kidney transplants between 1 January 2000 and 1 January 2021. Main OutcOMe Measure The main outcome measure was GFR, measured according to local practice. Performance of the GFR equations was assessed using P30 (proportion of estimated GFR (eGFR) within 30% of measured GFR (mGFR)) and correct classification (agreement between eGFR and mGFR according to GFR stages). The race-free equation, based on creatinine level, age, and sex, was developed using additive and multiplicative linear regressions, and its performance was compared with the three current main GFR equations: Modification of Diet in Renal Disease (MDRD) equation, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation, and race-free CKD-EPI 2021 equation. results The study included 15 489 participants, with 50 464 mGFR and eGFR values. The mean GFR was 53.18 mL/min/1.73m2 (SD 17.23) in the development cohort and 55.90 mL/min/1.73m2 (19.69) in the external validation cohorts. Among the current GFR equations, the race-free CKD-EPI 2021 equation showed the lowest performance compared with the MDRD and CKD-EPI 2009 equations. When race was included in the kidney recipient specific GFR equation, performance did not increase. The race-free kidney recipient specific GFR equation showed significantly improved performance compared with the race-free CKD-EPI 2021 equation and performed well in the external validation cohorts (P30 ranging from 73.0% to 91.3%). The race-free kidney recipient specific GFR equation performed well in several subpopulations of kidney transplant recipients stratified by race (P30 73.0-91.3%), sex (72.7-91.4%), age (70.3-92.0%), body mass index (64.5-100%), donor type (58.5-92.9%), donor age (68.3-94.3%), treatment (78.5-85.2%), creatinine level (72.8-91.3%), GFR measurement method (73.0-91.3%), and timing of GFR measurement post-transplant (72.9-95.5%). An online application was developed that estimates GFR based on recipient’s creatinine level, age, and sex (https://transplant-prediction-system.shinyapps.io/eGFR_equation_KTX/). cOnclusiOn A new race-free kidney recipient specific GFR equation was developed and validated using multiple, large, international cohorts of kidney transplant recipients. The equation showed high accuracy and outperformed the race-free CKD-EPI 2021 equation that was developed in individuals with native kidneys. trial registratiOn ClinicalTrials.gov NCT05229939.
UR - https://www.scopus.com/pages/publications/85160755713
UR - https://www.scopus.com/pages/publications/85160755713#tab=citedBy
U2 - 10.1136/bmj-2022-073654
DO - 10.1136/bmj-2022-073654
M3 - Article
C2 - 37257905
AN - SCOPUS:85160755713
SN - 0959-8146
VL - 381
JO - BMJ
JF - BMJ
M1 - e073654
ER -